263 related articles for article (PubMed ID: 18938143)
1. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.
Beurel E; Blivet-Van Eggelpoël MJ; Kornprobst M; Moritz S; Delelo R; Paye F; Housset C; Desbois-Mouthon C
Biochem Pharmacol; 2009 Jan; 77(1):54-65. PubMed ID: 18938143
[TBL] [Abstract][Full Text] [Related]
2. 1-Methoxy-canthin-6-one induces c-Jun NH2-terminal kinase-dependent apoptosis and synergizes with tumor necrosis factor-related apoptosis-inducing ligand activity in human neoplastic cells of hematopoietic or endodermal origin.
Ammirante M; Di Giacomo R; De Martino L; Rosati A; Festa M; Gentilella A; Pascale MC; Belisario MA; Leone A; Turco MC; De Feo V
Cancer Res; 2006 Apr; 66(8):4385-93. PubMed ID: 16618764
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 mediates acetaminophen-induced apoptosis in human hepatoma cells.
Macanas-Pirard P; Yaacob NS; Lee PC; Holder JC; Hinton RH; Kass GE
J Pharmacol Exp Ther; 2005 May; 313(2):780-9. PubMed ID: 15665138
[TBL] [Abstract][Full Text] [Related]
5. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
7. P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes.
De Toni EN; Kuntzen C; Gerbes AL; Thasler WE; Sonuc N; Mucha SR; Camaj P; Bruns C; Göke B; Eichhorst ST
J Hepatol; 2007 Apr; 46(4):682-91. PubMed ID: 17224200
[TBL] [Abstract][Full Text] [Related]
8. GSK-3 inhibitors enhance TRAIL-mediated apoptosis in human gastric adenocarcinoma cells.
Wu YY; Hsieh CT; Chiu YM; Chou SC; Kao JT; Shieh DC; Lee YJ
PLoS One; 2018; 13(12):e0208094. PubMed ID: 30557366
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
Zhang B; Shan H; Li D; Li ZR; Zhu KS; Jiang ZB; Huang MS
Oncol Rep; 2011 Feb; 25(2):461-8. PubMed ID: 21152876
[TBL] [Abstract][Full Text] [Related]
10. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trautwein C; Michalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Müller M
Cancer Res; 2006 Jul; 66(14):7059-66. PubMed ID: 16849551
[TBL] [Abstract][Full Text] [Related]
12. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage.
Jin CY; Park C; Moon SK; Kim GY; Kwon TK; Lee SJ; Kim WJ; Choi YH
Anticancer Drugs; 2009 Sep; 20(8):713-22. PubMed ID: 19617819
[TBL] [Abstract][Full Text] [Related]
13. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
14. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4.
Caja L; Sancho P; Bertran E; Iglesias-Serret D; Gil J; Fabregat I
Cancer Res; 2009 Oct; 69(19):7595-602. PubMed ID: 19773433
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
16. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines.
Mikami T; Koyama T; Koyama T; Imakiire A; Yamamoto K; Furuhata M; Toyota H; Mizuguchi J
Anticancer Res; 2006; 26(2A):1153-60. PubMed ID: 16619517
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
18. Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis.
Nakao K; Hamasaki K; Ichikawa T; Arima K; Eguchi K; Ishii N
Oncol Rep; 2006 Aug; 16(2):389-92. PubMed ID: 16820920
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta-mediated tumor necrosis factor-related apoptosis-inducing ligand expression and apoptosis in hepatoma cells requires functional cooperation between Smad proteins and activator protein-1.
Herzer K; Grosse-Wilde A; Krammer PH; Galle PR; Kanzler S
Mol Cancer Res; 2008 Jul; 6(7):1169-77. PubMed ID: 18644981
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of TRAIL-mediated apoptosis by anisomycin in human hepatoma cells via the BH3-only protein Bid and c-Jun/AP-1 signaling pathway.
Jin CY; Park C; Hong SH; Han MH; Jeong JW; Xu H; Liu H; Kim GY; Kim WJ; Yoo YH; Choi YH
Biomed Pharmacother; 2013 May; 67(4):321-8. PubMed ID: 23582782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
